Evidence map›Paper›PMID 35927178›Full record

ArticleProteins2023

Engineering human JMJD2A tudor domains for an improved understanding of histone peptide recognition.

Jonathan Parkinson, Ryan Hard, Richard Ainsworth, Wei Wang

Open access · greenAbstract read
In one paragraph

Article in Proteins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jonathan ParkinsonDepartment of Chemistry and Biochemistry, University of California San Diego, San Diego, California, USA.ORCID 0000-0002-7000-2082
Ryan HardDepartment of Chemistry and Biochemistry, University of California San Diego, San Diego, California, USA.
Richard AinsworthDepartment of Chemistry and Biochemistry, University of California San Diego, San Diego, California, USA.
Wei WangDepartment of Chemistry and Biochemistry, University of California San Diego, San Diego, California, USA.
University of California San Diego · US

Funding

Designing neutralization antibodies against Sars-Cov-2R21AI158114 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WANG, WEI · 2020 to 2020
$434k
NIAID NIH HHS R21 AI158114
6 · The paper itself

Abstract

JMJD2A is a histone lysine demethylase which recognizes and demethylates H3K9me3 and H3K36me3 residues and is overexpressed in various cancers. It utilizes a tandem tudor domain to facilitate its own recruitment to histone sites, recognizing various di- and tri-methyl lysine residues with moderate affinity. In this study, we successfully engineered the tudor domain of JMJD2A to specifically bind to H4K20me3 with a 20-fold increase of affinity and improved selectivity. To reveal the molecular basis, we performed molecular dynamics and free energy decomposition analysis on the human JMJD2A tandem tudor domains bound to H4K20me2, H4K20me3, and H3K23me3 peptides to uncover the residues and conformational changes important for the enhanced binding affinity and selectivity toward H4K20me2/3. These analyses revealed new insights into understanding chromatin reader domains recognizing histone modifications and improving binding affinity and selectivity of these domains. Furthermore, we showed that the tight binding of JMJD2A to H4K20me2/3 is not sufficient to improve the efficiency of CRISPR-CAS9 mediated homology directed repair (HDR), suggesting a complicated relationship between JMJD2A and the DNA damage response beyond binding affinity toward the H4K20me2/3 mark.

Indexed as

HistonesJumonji Domain-Containing Histone DemethylasesHumansMethylationPeptidesHistonesJumonji Domain-Containing Histone DemethylasesPeptidesCRISPRepigeneticshistoneJMJD2Amolecular dynamics

Identifiers

PMID35927178
PMCPMC9771871
OpenAlexW4289816423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.